Background: An increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …

Methods: This study included 71 NSCLC patients who received EGFR-TKIs between 2013
and 2016. Adverse drug reaction of both erlotinib (n= 37) and gefitinib (n= 34) was …

Background: The meta-analysis aimed to compare the efficacy and safety of erlotinib versus
(vs.) chemotherapy (docetaxel/pemetrexed) as second-line therapy in advanced non-small …

Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

Results of analysis show that even patients without EGFR mutation are able to benefit from
erlotinib treatment in the second line. The efficacy (DCR, PFS) of erlotinib in patients without …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the
first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the …